Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
1(8%)
Results Posted
67%(4 trials)
Terminated
3(23%)

Phase Distribution

Ph early_phase_1
1
8%
Ph not_applicable
2
15%
Ph phase_1
2
15%
Ph phase_2
2
15%
Ph phase_4
5
38%

Phase Distribution

3

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 4Post-market surveillance
5(41.7%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Completed6
Terminated3
unknown2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 12 (16.7%)
Phase 22 (16.7%)
Phase 45 (41.7%)
N/A2 (16.7%)

Trials by Status

withdrawn18%
completed646%
active_not_recruiting18%
unknown215%
terminated323%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13